Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study of the Combination of Inotuzumab Ozogamicin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)

Next Previous
Trial Profile

Phase I/II Study of the Combination of Inotuzumab Ozogamicin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inotuzumab ozogamicin (Primary) ; Ursodeoxycholic acid (Primary) ; Blinatumomab; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Mercaptopurine; Mesna; Methotrexate; Methotrexate; Methotrexate; Pegfilgrastim; Prednisone; Rituximab; Vincristine
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 12 Dec 2023 Updated Results (As of June 2023, n=75 ) presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results (n=71)presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 15 Jun 2023 Results (n=110) presented at the 28th Congress of the European Haematology Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top